

Hypertrophic Cardiomyopathy in Argentina: Centers of Excellence in Hypertrophic Cardiomyopathy in Latin America? What is the Meaning of Late Enhancement?

Miocardopatía hipertrófica en la Argentina: ¿Centros de excelencia en miocardopatía hipertrófica en América Latina? ¿Cuál es el significado del realce tardío?

PEDRO GRAZIANO¹

Since its initial description by Teare, hypertrophic cardiomyopathy (HCM) has fascinated and surprised many by its enigmatic hemodynamics, extremely variable phenotypic expression and sometimes unpredictable clinical manifestations, though the understanding of its natural evolution has been evaluated in several observational studies by different groups worldwide. (1) Today we know that most patients can have an excellent quality of life, a normal life expectancy and treatment with drug therapy, and symptomatic patients in advanced functional class, with left ventricular outflow tract obstruction, benefit from myectomy and alcohol septal ablation, improving functional class and, in some cases, preventing mortality. (2, 3)

The work of Costabel et al. of the Instituto Cardiovascular de Buenos Aires (ICBA) (4) published in this issue of the Journal is unprecedented, since it shows a large series of 259 patients in Latin America with median longitudinal mid-term follow-up of 3.5 years (2-10 years), performed by a group of physicians dedicated to the management of patients with HCM. Most of this experience is consistent with that previously described by different groups, but this work shows a fact that deserves to be rescued. Interestingly, it shows a high prevalence of apical HCM (27%), similar to that described in Japan (5) and not previously described in the Western world, raising the need for the characterization of the natural evolution of this subgroup of patients in Argentina and their genotypic correlation, which might indicate the path to follow with these patients.

Documented as a disease with high risk of peripheral and central embolism, this series shows a total embolism rate of 1.15% (3/259 patients) with two peripheral events and one stroke, slightly less than in some previous studies, showing a stroke rate of 1.4% (0.24% per year), (6, 7) although the ICBA population is relatively young (56 ± 16.8 years), with atrial fibrillation (5.4%), relatively small left atria [38 mm (28-48)] and under anticoagulation therapy. It should

be acknowledged that in previous series central embolisms are the leading cause of death in patients older than 70 years and that it is essential to lower the anticoagulation threshold in patients with large left atria (> 45 mm), paroxysmal or permanent supraventricular arrhythmias, and over 60 years of age. (6) The use of the CHA₂DS₂-VASc score is not recommended to guide anticoagulation therapy in these patients. (8)

The management of symptomatic patients with HCM has progressed in the last six decades due to the efforts focused on establishing the pathophysiology and developing the necessary skills to improve prognosis.

The creation of a center of excellence for the management of patients with HCM in Latin America represents a challenge and the group of ICBA seems to have faced the task, which is encouraging and inspiring for the whole region; however, the study shows some aspects of the long way to go in order to become a center of excellence at the highest level worldwide. Although the results are encouraging and of increasing experience, it has still a very limited number of myectomies (15 cases) and alcohol septal ablations (22 cases), with an ablation: myectomy ratio of 1.5: 1. The main centers of the world show an inverted myectomy: ablation relationship of approximately 10: 1. The results achieved in the main centers of HCM are impressive. (9)

Although surgical myectomy mortality data in ICBA is unknown, the mortality rate in the two main centers of global reference is close to 0%, with an approximate series of 130-140 or more cases per year. (9) This is only possible with continuous work, increasing the number of surgical cases and with the dedication of one or at most two surgeons to treat these patients with pre-established perioperative management protocols. We wish to see the growth of ICBA as HCM management center and know their mid- and long term surgical results.

In this issue of the Argentine Journal of Cardiol-

REV ARGENT CARDIOL 2016;84:191-192. <http://dx.doi.org/10.7775/rac.v84.i3.8591>

SEE RELATED ARTICLE: Rev Argent Cardiol 2016;84:202-208. <http://dx.doi.org/10.7775/rac.v84.i3.7168>

SEE RELATED ARTICLE: Rev Argent Cardiol 2016;84:215-220. <http://dx.doi.org/10.7775/rac.v84.i3.7431>

¹ Cardiologist. Cardiologic Medical Assistant, University Hospital of Caracas. Venezuela e-mail: pedrograziano@gmail.com

ogy, Deviggiano et al. (10) reproduce the information obtained from studies with cardiac magnetic resonance (CMR) in HCM, showing late gadolinium enhancement (LGE) in two thirds of patients, associated with maximum myocardial thickness but not with ventricular mass, and more common in the areas of hypertrophy. This finding confirms that HCM is a fibrosing disease and, above all, located at the basal and mid inferior septum and at the mid-anterior septal level.

Late gadolinium enhancement was observed in 30 (71%) patients with HCM and 141/672 (21%) of the segments evaluated. Its distribution was predominantly intramyocardial (n=103; 73%) and, less frequently, subendocardial (n=24; 17%), epicardial (n=10; 7%) and transmural (n=4; 3%).

Although several studies have promoted LGE as a possible marker for risk of sudden death, its extent is unequivocally associated with cardiovascular mortality, but not with sudden death, (11-13) so European guidelines do not support its use for such purpose. (8)

Late gadolinium enhancement can provide prognostic information and clinical practice guidelines support the use of MRI in all patients with HCM and in first-degree relatives, especially performed in centers with experience in this imaging technique. (8) However, there is still need to close the gap between guideline recommendations and clinical practice with studies that substantiate the value of MRI and its impact on clinical decision-making, upon which many questions still remain unanswered and, more importantly, if these variables are undeniably associated with prognosis and type of outcomes. The answer to these questions will be probably helped by the results of an ongoing registry with more than 2,750 patients from four countries, assessing LGE in this extensive series. (14)

Another missing link in almost all HCM registries is the study of coronary artery disease in the so-called HCM-unrelated mortality. Few prospectively studies have evaluated the impact of coronary artery disease on HCM-unrelated mortality; however, a study from the Mayo Clinic showed poor prognosis in this subgroup of patients. (15) The proper characterization of this subset of cases is a debt with clinical cardiology.

Conflicts of interest

None declared.

(See authors' conflicts of interest forms in the website/Supplementary material).

REFERENCES

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br Heart J* 1958;20:1-8. <http://doi.org/b38bqc>
2. Maron MS, Rowin EJ, Olivetto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2016;67:1399-409. <http://doi.org/bhmn>
3. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. *Heart Rhythm* 2016;13:1155-65. <http://doi.org/bhmp>
4. Costabel JP, Ametrano MC, Vrancic M, Cura F, Talavera ML, Acosta A et al. Long-term Outcome of Patients with Hypertrophic Cardiomyopathy. *Rev Argent Cardiol* 2016;84:215-20.
5. Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. *Am J Cardiol* 1979;44:401-12. <http://doi.org/bpvktj>
6. Maron BJ, Olivetto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;39:301-7. <http://doi.org/dwhkge>
7. Haruki S, Minami Y, Hagiwara N. Stroke and embolic events in hypertrophic cardiomyopathy: risk stratification in patients without atrial fibrillation. *Stroke* 2016;47:936-42. <http://doi.org/bhmq>
8. Elliott P. The new European Society of Cardiology guidelines on hypertrophic cardiomyopathy. *Heart* 2015;101:506-8. <http://doi.org/bhmr>
9. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. *J Am Coll Cardiol* 2015;66:1307-8. <http://doi.org/f3hx27>
10. Deviggiano A, Carrascosa P, De Zan M, Capuñay C, Deschle H, Rodríguez Granillo GA. Wall Thickness and Patterns of Fibrosis in Hypertrophic Cardiomyopathy Assessed by Cardiac Magnetic Resonance Imaging. *Rev Argent Cardiol* 2016;84:202-8.
11. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. *J Am Coll Cardiol* 2008;51:1369-74. <http://doi.org/d7xws9>
12. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. *Circ Heart Fail* 2010;3:51-8. <http://doi.org/fjnk78>
13. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;56:867-74. <http://doi.org/bkx3sz>
14. Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, DiMarco JP, Friedrich MG, et al. Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. *Am Heart J* 2015;170:223-30. <http://doi.org/bhms>
15. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. *Circulation* 2003;108:2342-8. <http://doi.org/c8xmdj>